Roberts R, Ishikawa Y
Circulation. 1983 Aug;68(2 Pt 2):I83-9.
Infarct size estimated enzymatically is an objective end point for assessing interventions in patients with acute myocardial infarction and correlates with acute and long-term morbidity and mortality. However, there is concern whether such estimates are reliable in the setting of reperfusion. Reperfusion during experimental infarction and clinically with streptokinase is associated with higher plasma creatine kinase (CK) levels that peak much earlier than with sustained occlusion, indicating a more rapid release rate. In this report, experimental derivation of the parameters for estimating infarct size--myocardial CK distribution and content, CK depletion, plasma CK disappearance rate and the release ratio--are presented, together with the experimental and clinical validation of these estimates. The close correlation between myocardial CK depletion and morphometric estimates of infarct size (r = .92), which provides the basis for enzymatic estimation of infarct size, remains valid during experimental reperfusion. Plasma CK activity (100-5000 IU/l) assayed before and after incubation of streptokinase (5000 U/ml for 30 minutes at 37 degrees C) showed less than 5% variation. Plasma CK disappearance (kd) in the conscious dog before and during infusion of streptokinase (20,000 U/hour) were identical. The CK release ratio has not been determined during streptokinase therapy or experimental reperfusion, but in the experimental animal during early reperfusion, infarct size was overestimated by the plasma CK method compared with histologic estimates. Despite the overestimation, enzymatic estimates still correlate closely with histologic estimates (r = .90). The presence of a close correlation despite sudden complete early restoration of flow suggests that with the appropriate experimentally determined correction factors, one can obtain reliable enzymatic estimates of infarct size to assess the efficacy of streptokinase.
通过酶学方法估算梗死面积是评估急性心肌梗死患者干预措施的一个客观终点,并且与急性和长期的发病率及死亡率相关。然而,对于在再灌注情况下这种估算是否可靠存在疑虑。实验性梗死期间以及临床上使用链激酶进行再灌注时,血浆肌酸激酶(CK)水平会升高,且峰值出现的时间比持续性闭塞时早得多,这表明释放速率更快。在本报告中,介绍了用于估算梗死面积的参数——心肌CK分布和含量、CK耗竭、血浆CK消失率及释放率——的实验推导过程,以及这些估算值的实验和临床验证情况。心肌CK耗竭与梗死面积的形态学估算值之间密切相关(r = 0.92),这为梗死面积的酶学估算提供了基础,在实验性再灌注期间该相关性依然成立。在37℃下用链激酶(5000 U/ml)孵育30分钟前后测定的血浆CK活性(100 - 5000 IU/l)显示变化小于5%。在清醒犬输注链激酶(20,000 U/小时)之前及期间,血浆CK消失率(kd)是相同的。在链激酶治疗或实验性再灌注期间尚未确定CK释放率,但在实验动物早期再灌注期间,与组织学估算相比,血浆CK方法高估了梗死面积。尽管存在高估情况,但酶学估算值仍与组织学估算值密切相关(r = 0.90)。尽管血流在早期突然完全恢复,但仍存在密切相关性,这表明通过适当的实验确定的校正因子,能够获得可靠的梗死面积酶学估算值以评估链激酶的疗效。